Tumor Biology

, Volume 36, Issue 3, pp 2179–2184 | Cite as

PPM1D overexpression predicts poor prognosis in non-small cell lung cancer

Research Article

Abstract

It has been reported that protein phosphatase, Mg2+/Mn2+ dependent, 1D (PPM1D) plays an important role in cancer tumorigenesis. However, the clinical and functional significance of PPM1D expression has not been characterized previously in non-small cell lung cancer (NSCLC). The purpose of this study was to assess PPM1D expression and to explore its contribution to NSCLC. We examined PPM1D messenger RNA (mRNA) expression in 53 NSCLC tissues and matched adjacent noncancerous tissues by quantitative reverse transcription PCR (qRT-PCR). Furthermore, the PPM1D protein expression was analyzed by immunohistochemistry in 157 NSCLC samples. The relationship between PPM1D expression and clinicopathological features was analyzed by appropriate statistics. Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between PPM1D expression and prognosis of NSCLC patients. The relative mRNA expression of PPM1D was significantly elevated in NSCLC tissues as compared with adjacent noncancerous tissues (P < 0.001). The high expression of PPM1D in NSCLC tissues was significantly correlated with tumor grade (P = 0.006), tumor size (P = 0.017), clinical stage (P = 0.001), and lymph node metastases (P = 0.002). Kaplan-Meier survival analysis revealed that high PPM1D expression correlated with poor prognosis of NSCLC patients (P < 0.001). Multivariate analysis showed that PPM1D expression was an independent prognostic marker for overall survival of NSCLC patients. In conclusion, PPM1D plays an important role in the progression of NSCLC. PPM1D may potentially be used as an independent biomarker for the prognostic evaluation of NSCLC.

Keywords

PPM1D NSCLC Biomarker Prognosis 

Notes

Conflicts of interest

None

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50. doi: 10.1200/JCO.2005.05.2308.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49. doi: 10.3322/caac.20006.CrossRefPubMedGoogle Scholar
  3. 3.
    Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 2007;25(34):5506–18. doi: 10.1200/JCO.2007.14.1226.CrossRefPubMedGoogle Scholar
  4. 4.
    Lu G, Wang Y. Functional diversity of mammalian type 2C protein phosphatase isoforms: new tales from an old family. Clin Exp Pharmacol Physiol. 2008;35:107–12. doi: 10.1111/j.1440-1681.2007.04843.x.CrossRefPubMedGoogle Scholar
  5. 5.
    Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 2002;31:210–5. doi: 10.1038/ng894.CrossRefPubMedGoogle Scholar
  6. 6.
    Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet. 2002;31:133–4. doi: 10.1038/ng888.CrossRefPubMedGoogle Scholar
  7. 7.
    Lu X, Nguyen TA, Appella E, Donehower LA. Homeostatic regulation of base excision repair by a p53-induced phosphatase: linking stress response pathways with DNA repair proteins. Cell Cycle. 2004;3:1363–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, et al. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 2008;86:245–56. doi: 10.1007/s11060-007-9470-8.CrossRefPubMedGoogle Scholar
  9. 9.
    Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 2003;63:1876–83.PubMedGoogle Scholar
  10. 10.
    Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci. 2007;98:392–400. doi: 10.1111/j.1349-7006.2007.00395.x.CrossRefPubMedGoogle Scholar
  11. 11.
    Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 2009;15:2269–80. doi: 10.1158/1078-0432.CCR-08-2403.CrossRefPubMedGoogle Scholar
  12. 12.
    Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G, et al. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat. 2007;101:269–78.CrossRefPubMedGoogle Scholar
  13. 13.
    Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjärvi T, Kallioniemi A. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat. 2006;95:257–63.CrossRefPubMedGoogle Scholar
  14. 14.
    Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Yoshimura M, et al. Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci. 2011;102:1101–6. doi: 10.1111/j.1349-7006.2011.01898.x.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang C, Chen Y, Wang M, Chen X, Li Y, Song E, et al. PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells. World J Surg Oncol. 2014;12:258. doi: 10.1186/1477-7819-12-258.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tu L, Liu Z, He X, He Y, Yang H, Jiang Q, et al. Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Mol Cancer. 2010;9:78. doi: 10.1186/1476-4598-9-78.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270. doi: 10.1186/1471-2407-10-270.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zhong X, Li M, Nie B, Wu F, Zhang L, Wang E, et al. Overexpressions of RACK1 and CD147 associated with poor prognosis in stage T1 pulmonary adenocarcinoma. Ann Surg Oncol. 2013;20:1044–52. doi: 10.1245/s10434-012-2377-4.CrossRefPubMedGoogle Scholar
  19. 19.
    Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature. 2009;460:278–82. doi: 10.1038/nature08136.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Niu Y, Liu T, Tse GM, Sun B, Niu R, Li HM, et al. Increased expression of centrosomal alpha, gamma-tubulin in atypical ductal hyperplasia and carcinoma of the breast. Cancer Sci. 2009;100:580–7. doi: 10.1111/j.1349-7006.2008.01075.x.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Hua Yang
    • 1
  • Xiao-Yu Gao
    • 2
  • Ping Li
    • 1
  • Ting-Shu Jiang
    • 3
  1. 1.Respiratory DepartmentYantai Hospital of Traditional Chinese MedicineYantaiChina
  2. 2.Neurology DepartmentYantai Yuhuangding Hospital Affiliated to Qingdao UniversityYantaiChina
  3. 3.Respiratory DepartmentYantai Yuhuangding Hospital Affiliated to Qingdao UniversityYantaiChina

Personalised recommendations